File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/bcp.16221
- Scopus: eid_2-s2.0-85204722025
- WOS: WOS:001321285300001
- Find via

Supplementary
- Citations:
- Appears in Collections:
Article: Altered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease
| Title | Altered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease |
|---|---|
| Authors | |
| Keywords | chronic kidney disease drug interactions drug transporters hepatotoxicity mass spectrometry |
| Issue Date | 1-Feb-2025 |
| Publisher | Wiley |
| Citation | British Journal of Clinical Pharmacology, 2025, v. 91, n. 2, p. 353-364 How to Cite? |
| Abstract | Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non-clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug-induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin-I (CP-I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B-mediated DDI risk in humans. In this clinical observational cohort-comparison study, bile acid profiles and CP-I concentrations in healthy volunteers and patients with ADPKD were compared. Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP-I concentrations, were quantified by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3-fold) and taurine-conjugated (2.8-fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5-, 2.9-, 2.8-, 1.6-, 1.7- and 2.7-fold, respectively) in patients with ADPKD. Furthermore, serum CP-I concentrations were elevated and the renal clearance of CP-I was reduced in patients with ADPKD compared to healthy volunteers. Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP-I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers. |
| Persistent Identifier | http://hdl.handle.net/10722/358210 |
| ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 1.046 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tiley, Jacqueline B | - |
| dc.contributor.author | Beaudoin, James J | - |
| dc.contributor.author | Derebail, Vimal K | - |
| dc.contributor.author | Murphy, William A | - |
| dc.contributor.author | Park, Christine C | - |
| dc.contributor.author | Veeder, Justin A | - |
| dc.contributor.author | Tran, Lana | - |
| dc.contributor.author | Beers, Jessica L | - |
| dc.contributor.author | Jia, Wei | - |
| dc.contributor.author | Stewart, Paul W | - |
| dc.contributor.author | Brouwer, Kim LR | - |
| dc.date.accessioned | 2025-07-26T00:30:22Z | - |
| dc.date.available | 2025-07-26T00:30:22Z | - |
| dc.date.issued | 2025-02-01 | - |
| dc.identifier.citation | British Journal of Clinical Pharmacology, 2025, v. 91, n. 2, p. 353-364 | - |
| dc.identifier.issn | 0306-5251 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/358210 | - |
| dc.description.abstract | Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non-clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug-induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin-I (CP-I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B-mediated DDI risk in humans. In this clinical observational cohort-comparison study, bile acid profiles and CP-I concentrations in healthy volunteers and patients with ADPKD were compared. Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP-I concentrations, were quantified by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3-fold) and taurine-conjugated (2.8-fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5-, 2.9-, 2.8-, 1.6-, 1.7- and 2.7-fold, respectively) in patients with ADPKD. Furthermore, serum CP-I concentrations were elevated and the renal clearance of CP-I was reduced in patients with ADPKD compared to healthy volunteers. Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP-I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers. | - |
| dc.language | eng | - |
| dc.publisher | Wiley | - |
| dc.relation.ispartof | British Journal of Clinical Pharmacology | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | chronic kidney disease | - |
| dc.subject | drug interactions | - |
| dc.subject | drug transporters | - |
| dc.subject | hepatotoxicity | - |
| dc.subject | mass spectrometry | - |
| dc.title | Altered bile acid and coproporphyrin-I disposition in patients with autosomal dominant polycystic kidney disease | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1111/bcp.16221 | - |
| dc.identifier.scopus | eid_2-s2.0-85204722025 | - |
| dc.identifier.volume | 91 | - |
| dc.identifier.issue | 2 | - |
| dc.identifier.spage | 353 | - |
| dc.identifier.epage | 364 | - |
| dc.identifier.eissn | 1365-2125 | - |
| dc.identifier.isi | WOS:001321285300001 | - |
| dc.identifier.issnl | 0306-5251 | - |
